Cerebrospinal fluid Aβ40 improves the interpretation of Aβ42 concentration for diagnosing Alzheimer's disease

Frontiers in Neurology

Volumn 6, Issue NOV, 2015, Pages

  Dorey, Aline ^a,b   Perret Liaudet, Armand ^a,b   Tholance, Yannick ^a,b,c   Fourier, Anthony ^a,b   Quadrio, Isabelle ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Alzheimer; A 40; A 42; Cerebrospinal fluid; Dementia

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42];

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84949746920     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00247     Document Type: Article

References (49)

1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 7(3):263-9. doi: 10.1016/j.jalz.2011.03.005.
2. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol (2014) 13(6):614-29. doi:10.1016/S1474-4422(14)70090-0.
3. Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol (2010) 17(10):1236-48. doi:10.1111/j.1468-1331.2010.03040.x.
4. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 9(11):1118-27. doi:10.1016/S1474-4422(10)70223-4.
5. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 7(3):270-9. doi:10.1016/j.jalz.2011.03.008.
6. Seguin J, Formaglio M, Perret-Liaudet A, Quadrio I, Tholance Y, Rouaud O, et al. CSF biomarkers in posterior cortical atrophy. Neurology (2011) 76(21):1782-8. doi:10.1212/WNL.0b013e31821ccc98.
7. Lehmann S, Schraen S, Quadrio I, Paquet C, Bombois S, Delaby C, et al. Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. Alzheimers Dement (2013) 10(5 Suppl):S390-4. doi:10.1016/j.jalz.2013.06.008.
8. Molinuevo JL, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perret-Liaudet A, et al. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement (2014) 10(6):808-17. doi:10.1016/j.jalz.2014.03.003.
9. Mo JA, Lim JH, Sul AR, Lee M, Youn YC, Kim HJ. Cerebrospinal fluid beta-amyloid1-42 levels in the differential diagnosis of Alzheimer's disease-systematic review and meta-analysis. PLoS One (2015) 10(2):e0116802. doi:10.1371/journal.pone.0116802.
10. Rosen C, Farahmand B, Skillback T, Nagga K, Mattsson N, Kilander L, et al. Benchmarking biomarker-based criteria for Alzheimer's disease: data from the Swedish Dementia Registry, SveDem. Alzheimers Dement (2015). doi:10.1016/j.jalz.2015.04.007.
11. Wiltfang J, Esselmann H, Bibl M, Hull M, Hampel H, Kessler H, et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low-and high-CSF A beta 40 load. J Neurochem (2007) 101(4):1053-9. doi:10.1111/j.1471-4159.2006.04404.x.
12. Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem (2002) 81(3):481-96. doi:10.1046/j.1471-4159.2002.00818.x.
13. Spies PE, Slats D, Sjogren JM, Kremer BP, Verhey FR, Rikkert MG, et al. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. Curr Alzheimer Res (2010) 7(5):470-6. doi:10.2174/156720510791383796.
14. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry (2010) 15(2):138-45. doi:10.1038/mp.2008.84.
15. Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res (2006) 5(4):1010-6. doi:10.1021/pr050475v.
16. Otto M, Lewczuk P, Wiltfang J. Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. Methods (2008) 44(4):289-98. doi:10.1016/j.ymeth.2007.06.012.
17. Gravina SA, Ho L, Eckman CB, Long KE, Otvos L Jr, Younkin LH, et al. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem (1995) 270(13):7013-6.
18. Lewczuk P, Wiltfang J. Neurochemical dementia diagnostics: state of the art and research perspectives. Proteomics (2008) 8(6):1292-301. doi:10.1002/pmic.200700703.
19. Verbeek MM, De Jong D, Kremer HP. Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. Ann Clin Biochem (2003) 40(Pt 1):25-40. doi:10.1258/000456303321016141.
20. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, et al. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord (2007) 23(5):316-20. doi:10.1159/000100926.
21. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol (2000) 57(1):100-5. doi:10.1001/archneur.57.1.100.
22. Shoji M, Matsubara E, Kanai M, Watanabe M, Nakamura T, Tomidokoro Y, et al. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci (1998) 158(2):134-40. doi:10.1016/S0022-510X(98)00122-1.
23. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol (1998) 44(1):17-26. doi:10.1002/ana.410440108.
24. Fukuyama R, Mizuno T, Mori S, Nakajima K, Fushiki S, Yanagisawa K. Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients. Eur Neurol (2000) 43(3):155-60. doi:10.1159/000008157.
25. Schoonenboom NS, Mulder C, Van Kamp GJ, Mehta SP, Scheltens P, Blankenstein MA, et al. Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same? Ann Neurol (2005) 58(1):139-42. doi:10.1002/ana.20508.
26. Slaets S, Le Bastard N, Martin JJ, Sleegers K, Van Broeckhoven C, De Deyn PP, et al. Cerebrospinal fluid Abeta1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. J Alzheimers Dis (2013) 36(4):759-67. doi:10.3233/JAD-130107.
27. Sauvee M, DidierLaurent G, Latarche C, Escanye MC, Olivier JL, Malaplate-Armand C. Additional use of Abeta(4)(2)/Abeta(4)(0) ratio with cerebrospinal fluid biomarkers P-tau and Abeta(4)(2) increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. J Alzheimers Dis (2014) 41(2):377-86. doi:10.3233/JAD-131838.
28. Dumurgier J, Schraen S, Gabelle A, Vercruysse O, Bombois S, Laplanche JL, et al. Cerebrospinal fluid amyloid-beta 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimers Res Ther (2015) 7(1):30. doi:10.1186/s13195-015-0114-5.
29. American-Psychiatric-Association. Diagnostic and Statistical Manual of Mental Disorders (IV-TR). 4th ed. Washington, DC: American-Psychiatric-Association (2000).
30. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 65(12):1863-72. doi:10.1212/01.wnl.0000187889.17253.b1.
31. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 134(Pt 9):2456-77. doi:10.1093/brain/awr179.
32. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement (2012) 8(1):65-73. doi:10.1016/j.jalz.2011.07.004.
33. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med (2012) 6(4):419-30. doi:10.2217/bmm.12.46.
34. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement (2013) 9(3):251-61. doi:10.1016/j.jalz.2013.01.010.
35. Metz CE. Basic principles of ROC analysis. Semin Nucl Med (1978) 8(4):283-98. doi:10.1016/S0001-2998(78)80014-2.
36. Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J. Amyloid-beta 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays. J Alzheimers Dis (2015) 43(1):183-91. doi:10.3233/JAD-140771.
37. Lewczuk P, Beck G, Esselmann H, Bruckmoser R, Zimmermann R, Fiszer M, et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem (2006) 52(2):332-4. doi:10.1373/clinchem.2005.058776.
38. Fourier A, Portelius E, Zetterberg H, Blennow K, Quadrio I, Perret-Liaudet A. Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarkers variability. Clin Chim Acta (2015) 449:9-15. doi:10.1016/j.cca.2015.05.024.
39. Grossman M, Farmer J, Leight S, Work M, Moore P, Van Deerlin V, et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol (2005) 57(5):721-9. doi:10.1002/ana.20477.
40. Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem Int (2009) 55(4):214-8. doi:10.1016/j.neuint.2009.02.017.
41. Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology (2012) 78(1):47-54. doi:10.1212/WNL.0b013e31823ed0f0.
42. de Souza LC, Lamari F, Belliard S, Jardel C, Houillier C, De Paz R, et al. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. J Neurol Neurosurg Psychiatry (2011) 82(3):240-6. doi:10.1136/jnnp.2010.207183.
43. Toledo JB, Brettschneider J, Grossman M, Arnold SE, Hu WT, Xie SX, et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol (2012) 124(1):23-35. doi:10.1007/s00401-012-0983-7.
44. Kovacs GG, Milenkovic I, Wohrer A, Hoftberger R, Gelpi E, Haberler C, et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol (2013) 126(3):365-84. doi:10.1007/s00401-013-1157-y.
45. Rahimi J, Kovacs GG. Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther (2014) 6(9):82. doi:10.1186/s13195-014-0082-1.
46. Graff-Radford NR. Alzheimer CSF biomarkers may be misleading in normal-pressure hydrocephalus. Neurology (2014) 83(17):1573-5. doi:10.1212/WNL.0000000000000916.
47. Jeppsson A, Zetterberg H, Blennow K, Wikkelso C. Idiopathic normal-pressure hydrocephalus: pathophysiology and diagnosis by CSF biomarkers. Neurology (2013) 80(15):1385-92. doi:10.1212/WNL.0b013e31828c2fda.
48. Gabelle A, Roche S, Geny C, Bennys K, Labauge P, Tholance Y, et al. Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40 and 42 in human cerebrospinal fluid. Brain Res (2010) 1357:175-83. doi:10.1016/j.brainres.2010.08.022.
49. Gabelle A, Roche S, Geny C, Bennys K, Labauge P, Tholance Y, et al. Decreased sAbetaPPbeta, Abeta38, and Abeta40 cerebrospinal fluid levels in frontotemporal dementia. J Alzheimers Dis (2011) 26(3):553-63. doi:10.3233/JAD-2011-110515.